Landmark Vaccine Deals Signal Africa’s Shift Toward Local Manufacturing

Landmark Vaccine Deals Signal Africa’s Shift Toward Local Manufacturing

14 FEBRUARY 2025 – For the first time, an end-to-end mRNA vaccine production platform will be built in Africa, with plans to manufacture 100 million doses annually. A separate cross-continental partnership is advancing homegrown mRNA technology. These landmark agreements, signed in Cairo, are backed by a $1.2 billion investment from Gavi, The Vaccine Alliance. They aim to ensure vaccines are made by Africa, for Africa, and set the stage for expanded local vaccine production and cross-continental collaboration.